Telix Pharmaceuticals Limited

Telix is pleased to support the 3rd Annual Targeted Radiopharmaceuticals Summit US, which has started today in San Diego, CA. This event brings together key commercial and scientific industry leaders, to discuss the future of radiopharmaceuticals. Telix is featured on the line-up of expert speakers, exploring innovation in the sector from clinical development and trial design, to manufacturing and supply chain optimisation. To view the full event guide, visit: https://lnkd.in/eXjc43na #TRPSummit2024 #Radiopharmaceuticals

Telix is pleased to announce the opening of an expanded access program (EAP) in the U.S. for TLX101-CDx (Pixclara®, or 18F-floretyrosine), our investigational glioma (brain cancer) imaging product. This EAP will facilitate continued access to patients in the U.S., where there is significant unmet medical need. Visit our website for more: https://bit.ly/46rdnjN

Today, Telix was honoured to welcome the Governor of Indiana, Eric J. Holcomb, to our Global HQ in Melbourne, Australia. The Governor was able to learn more about Telix’s presence in Indiana and see theranostics in action at the nearby Melbourne Theranostic Innovation Centre. As the home of our U.S. business, Indiana’s central location, workforce talent and history in radiopharma have been pivotal in our commercial development. We thank the Victorian Government and the Indiana Government for their ongoing support in advancing nuclear medicine in the pursuit of patient care. Global Victoria Indiana Economic Development Corporation

Telix is pleased to announce that the FDA has accepted the filing of its New Drug Application for TLX007-CDx, a new cold kit for PSMA-PET imaging of prostate cancer. The Prescription Drug User Fee Act (PDUFA) goal date is March 24, 2025. If approved, the Kit will enable a considerably extended distribution radius compared with currently approved gallium-68 based agents. This filing acceptance is an important step towards further improving equity of access and reinforcing Telix’s commitment to innovation. More on our website: https://bit.ly/3WkagoU

Telix has successfully priced A$650 million of convertible bonds. The net proceeds are intended to provide funding to accelerate key clinical development programs and enable Telix to continue to invest in global supply chain and manufacturing capabilities. Read more on our website here: https://bit.ly/3Wz2zwl

Telix today launches an offering of A$600 million in convertible bonds. The offering will provide additional financial flexibility to execute on our strategic priorities and capitalise on future opportunities in the rapidly growing radiopharmaceuticals market. Read more on our website here: https://bit.ly/3SffocT Bonds will be listed on the Singapore Exchange (SGX) and convertible into fully paid ordinary shares in Telix on the Australian Securities Exchange (ASX).

Today marks an important milestone for Telix as we join the S&P/ASX 100 Index, effective prior to the open of trading. Standing with the top 100 companies on the ASX, we reaffirm our commitment to deliver on the promise of precision medicine through targeted radiation. We would like to thank everyone who has supported Telix’s journey to date, in pursuit of our purpose to help people with cancer and rare diseases live longer, better quality lives.

A recent paper published in Theranostics highlights positive results from a pre-clinical collaboration between Telix and Radboud University Medical Center (Radboudumc). Simone Kleinendorst and colleagues evaluated Telix’s investigational carbonic anhydrase IX (CAIX) targeting therapy, TLX250 (177Lu-girentuximab), in combination with two immune checkpoint inhibitors (ICI) for advanced clear cell renal cell carcinoma. The study found that TLX250 combined with ICI showed superior therapeutic outcomes and significantly altered the tumour microenvironment. Based on these results, TLX250 + ICI combination therapy is currently being investigated in the Phase II STARLITE-1 and 2 studies to validate the concept in humans. We recently sat down with one of the publication’s authors and Telix Director of ImmunoOncology Research, Kwame Twumasi-Boateng, to discuss the study and potential future directions for this novel therapy combination. Read the full paper on our Medical channel below, and visit our website for more on Telix’s CAIX-targeting theranostic portfolio: https://lnkd.in/g5jXyZbS

Congratulations to our friends at Mercy Radiology in New Zealand as they begin to image patients with Illuccix® on their brand-new mobile PET-CT unit - the first of its kind in the Southern Hemisphere! The availability of mobile PSMA-PET with Telix’s Illuccix® kit and a gallium generator marks a pivotal step towards ensuring broader access to advanced prostate cancer imaging in New Zealand’s underserved communities. Thanks to Mercy Radiology and Mobile Health Group for helping bridge the gap in prostate cancer care, so that local patients can receive timely and accurate diagnoses, no matter who or where they are. Mobile Imaging | Remy Lim | Jessica Fagan

Telix today issues a revenue and business update for the quarter ended 30 June 2024. Unaudited total revenue grew to US$124M, an increase of 55% on the prior corresponding quarter, primarily driven by U.S sales of Illuccix®. Accordingly, Telix has upgraded its revenue guidance for FY 2024. Key operational highlights include positive data from our prostate cancer therapy programs, TLX591 and TLX592, and significant advancements in our precision medicine portfolio with regulatory filings being progressed for new prostate, kidney and brain cancer imaging agents. For more details on our Q2 2024 results, visit: https://bit.ly/3Y69TRq